Trimetrexate: Difference between revisions
CSV import |
CSV import |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
== Trimetrexate = | {{Short description|An antineoplastic and antimicrobial agent}} | ||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| image = Trimetrexate.svg | |||
| image2 = | |||
}} | |||
[[ | '''Trimetrexate''' is a [[chemotherapeutic agent]] used primarily in the treatment of [[Pneumocystis pneumonia]] and certain types of [[cancer]]. It is a [[dihydrofolate reductase inhibitor]], which means it interferes with the enzyme responsible for the reduction of dihydrofolate to tetrahydrofolate, a form of [[folic acid]] necessary for the synthesis of [[nucleic acids]]. | ||
==Mechanism of Action== | |||
Trimetrexate works by inhibiting the enzyme [[dihydrofolate reductase]] (DHFR). This inhibition prevents the conversion of dihydrofolate to tetrahydrofolate, thereby depleting the cellular pools of tetrahydrofolate. As a result, the synthesis of [[thymidylate]] and [[purine nucleotides]] is disrupted, leading to impaired [[DNA synthesis]] and cell death. This mechanism is particularly effective against rapidly dividing cells, such as cancer cells and certain types of [[pathogenic microorganisms]]. | |||
== | ==Clinical Uses== | ||
Trimetrexate | Trimetrexate is primarily used in the treatment of: | ||
* [[Pneumocystis pneumonia]] (PCP) in patients who are intolerant to or have failed standard therapies such as [[trimethoprim-sulfamethoxazole]]. | |||
* Certain types of [[cancer]], including [[colorectal cancer]] and [[non-small cell lung cancer]]. | |||
==Administration and Dosage== | |||
Trimetrexate is administered intravenously. The dosage and duration of treatment depend on the specific condition being treated, the patient's response to therapy, and the presence of any adverse effects. It is often used in combination with [[leucovorin]] to mitigate the toxic effects on normal cells. | |||
== Side Effects == | ==Side Effects== | ||
Common side effects of trimetrexate include | Common side effects of trimetrexate include: | ||
== | * [[Myelosuppression]], leading to [[neutropenia]], [[thrombocytopenia]], and [[anemia]]. | ||
* [[Gastrointestinal disturbances]], such as [[nausea]], [[vomiting]], and [[diarrhea]]. | |||
* [[Hepatotoxicity]], which may manifest as elevated [[liver enzymes]]. | |||
==Precautions== | |||
Due to its potential for severe [[myelosuppression]], patients receiving trimetrexate should be closely monitored with regular [[blood tests]] to assess [[blood cell counts]]. The use of leucovorin is essential to protect normal cells from the toxic effects of trimetrexate. | |||
==Related pages== | |||
* [[Dihydrofolate reductase]] | * [[Dihydrofolate reductase]] | ||
* [[Pneumocystis pneumonia]] | * [[Pneumocystis pneumonia]] | ||
* [[ | * [[Chemotherapy]] | ||
* [[Antifolate]] | |||
[[Category: | [[Category:Antineoplastic and immunomodulating agents]] | ||
[[Category: | [[Category:Antimicrobial agents]] | ||
<gallery> | |||
File:Trimetrexate.svg|Trimetrexate | |||
</gallery> | |||
Latest revision as of 01:41, 20 February 2025
An antineoplastic and antimicrobial agent
| Trimetrexate | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Trimetrexate is a chemotherapeutic agent used primarily in the treatment of Pneumocystis pneumonia and certain types of cancer. It is a dihydrofolate reductase inhibitor, which means it interferes with the enzyme responsible for the reduction of dihydrofolate to tetrahydrofolate, a form of folic acid necessary for the synthesis of nucleic acids.
Mechanism of Action[edit]
Trimetrexate works by inhibiting the enzyme dihydrofolate reductase (DHFR). This inhibition prevents the conversion of dihydrofolate to tetrahydrofolate, thereby depleting the cellular pools of tetrahydrofolate. As a result, the synthesis of thymidylate and purine nucleotides is disrupted, leading to impaired DNA synthesis and cell death. This mechanism is particularly effective against rapidly dividing cells, such as cancer cells and certain types of pathogenic microorganisms.
Clinical Uses[edit]
Trimetrexate is primarily used in the treatment of:
- Pneumocystis pneumonia (PCP) in patients who are intolerant to or have failed standard therapies such as trimethoprim-sulfamethoxazole.
- Certain types of cancer, including colorectal cancer and non-small cell lung cancer.
Administration and Dosage[edit]
Trimetrexate is administered intravenously. The dosage and duration of treatment depend on the specific condition being treated, the patient's response to therapy, and the presence of any adverse effects. It is often used in combination with leucovorin to mitigate the toxic effects on normal cells.
Side Effects[edit]
Common side effects of trimetrexate include:
- Myelosuppression, leading to neutropenia, thrombocytopenia, and anemia.
- Gastrointestinal disturbances, such as nausea, vomiting, and diarrhea.
- Hepatotoxicity, which may manifest as elevated liver enzymes.
Precautions[edit]
Due to its potential for severe myelosuppression, patients receiving trimetrexate should be closely monitored with regular blood tests to assess blood cell counts. The use of leucovorin is essential to protect normal cells from the toxic effects of trimetrexate.
Related pages[edit]
-
Trimetrexate
